文献速递类风湿关节炎

治疗前钙卫蛋白(MRP8/14)对类风湿关节炎患者TNF抑制剂应答的预测并不优于单用C反应蛋白:一项事后分析

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.
PubMed 文献 · Ann Rheum Dis · 2023-02-21

在470例即将开始阿达木单抗(n=196)或依那西普(n=274)治疗的类风湿关节炎患者中,治疗前血清MRP8/14在3C和2C模型下与EULAR应答相关,但单用CRP预测时加入MRP8/14并未显著改善模型拟合,提示MRP8/14在CRP之外无额外预测价值。

要点

  • 治疗前MRP8/14高(第75百分位)较低(第25百分位)者在3C和2C模型下EULAR应答可能性更高(OR 1.92和2.03)。
  • 单用CRP时,高于第75百分位者在3C和2C分析中EULAR应答可能性分别为3.79倍和3.58倍。
  • 加入MRP8/14后模型拟合未显著改善(p=0.62和0.80),4C模型无显著关联。

核心结论

  • 除与CRP相关外,无证据表明MRP8/14在CRP之外能解释类风湿关节炎患者TNF抑制剂应答的额外变异。

研究设计与样本

  • 事后分析,测量470例即将开始阿达木单抗(n=196)或依那西普(n=274)治疗的类风湿关节炎患者的血清MRP8/14,并测量179例阿达木单抗治疗患者3个月时的血清MRP8/14。

主要发现

  • 在3C和2C模型中,治疗前MRP8/14高(第75百分位)较低(第25百分位)者EULAR应答可能性分别为1.92倍(CI:1.04至3.54)和2.03倍(CI:1.09至3.78)。
  • 单用CRP预测时,3C和2C分析中高于第75百分位者EULAR应答可能性分别为3.79倍(CI:1.81至7.93)和3.58倍(CI:1.74至7.35)。
  • 加入MRP8/14未显著改善模型拟合(p值分别为0.62和0.80)。
  • 从结局指标(CDAI)中排除CRP后,MRP8/14与应答无显著关联(OR 1.00(CI:0.99至1.01))。
  • 4C模型分析中未观察到显著关联。

关键数值与推荐

  • 应答采用欧洲抗风湿病联盟(EULAR)应答标准,基于传统4组分(4C)DAS28-CRP及验证的3组分(3C)和2组分(2C)版本、临床疾病活动指数(CDAI)改善标准及个体结局指标变化判定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The inflammatory protein calprotectin (MRP8/14) has been identified as a promising biomarker of treatment response in rheumatoid arthritis (RA). Our aim was to test MRP8/14 as a biomarker of response to tumour necrosis factor (TNF)-inhibitors in the largest RA cohort to date and to compare with C-reactive protein (CRP). METHODS: Serum MRP8/14 was measured in 470 patients with RA about to commence treatment with adalimumab (n=196) or etanercept (n=274). Additionally, MRP8/14 was measured in the 3-month sera of 179 adalimumab-treated patients. Response was determined using European League against Rheumatism (EULAR) response criteria calculated using the traditional 4-component (4C) DAS28-CRP and alternate validated versions using 3-component (3C) and 2-component (2C), clinical disease activity index (CDAI) improvement criteria and change in individual outcome measures. Logistic/linear regression models were fitted for response outcome. RESULTS: In the 3C and 2C models, patients with RA were 1.92 (CI: 1.04 to 3.54) and 2.03 (CI: 1.09 to 3.78) times more likely to be classified as EULAR responders if they had high (75th quartile) pre-treatment levels of MRP8/14 compared with low (25th quartile). No significant associations were observed for the 4C model. When only using CRP as a predictor, in the 3C and 2C analyses, patients above the 75th quartile were 3.79 (CI: 1.81 to 7.93) and 3.58 (CI: 1.74 to 7.35) times more likely to be EULAR responders and addition of MRP8/14 did not significantly improve model fit (p values=0.62 and 0.80, respectively). No significant associations were observed in the 4C analysis. Exclusion of CRP from the outcome measure (CDAI) did not result in any significant associations with MRP8/14 (OR 1.00 (CI: 0.99 to 1.01), suggesting that the associations were due to the correlation with CRP and that there is no additional utility of MRP8/14 beyond use of CRP in patients with RA starting TNFi therapy. CONCLUSION: Beyond correlation with CRP, we found no evidence to suggest that MRP8/14 explains additional variability in response to TNFi in patients with RA over and above CRP alone.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Smith SL, Alexander S, Nair N, et al. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis. Ann Rheum Dis. 2023. PMID: 36810200. doi:10.1136/ard-2022-222519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。